Amneal insider awarded 6.38M Class A shares
Amneal Pharmaceuticals, Inc. reported that President & Co-CEO Chirag K. Patel, through limited liability companies he manages, acquired 6,381,734 shares of Class A common stock on August 10, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Amneal Pharmaceuticals, Inc. reported that President & Co-CEO Chirag K. Patel, through limited liability companies he manages, acquired 6,381,734 shares of Class A common stock on August 10, 2026. These shares were issued as part of Amneal’s acquisition of Kashiv BioSciences, LLC. After the transactions, Patel is reported as holding 1,393,470 shares directly and additional Class A shares indirectly, including 21,269,420 shares held by family trusts.
Insider Trade Summary
Grant/Award: 6,381,734 shares
Grant/Award
3 txns
Insider
Patel Chirag K.
Role
President & Co-CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Class A Common Stock F1 | 6,381,734 | -- | -- |
| holding | Class A Common Stock | -- | -- | -- |
| holding | Class A Common Stock | -- | -- | -- |
Holdings After Transaction:
Class A Common Stock — 6,381,734 shares (Indirect, By Limited Liability Companies);
Class A Common Stock — 1,393,470 shares (Direct);
Class A Common Stock — 21,269,420 shares (Indirect, By Family Trusts)
Footnotes (1)
- F1. On August 10, 2026, pursuant to a Membership Interest Purchase Agreement, dated as of April 21, 2026 (as amended from time to time, the Purchase Agreement), by and among the Issuer, Kashiv BioSciences, LLC (Kashiv), KB Seller Representative, LLC and the equity holders of Kashiv named therein (the Sellers), a subsidiary of the Issuer purchased (the Acquisition) from the Sellers 100% of the issued and outstanding membership interests of Kashiv for an aggregate consideration of $375,000,000 in cash, subject to certain purchase price adjustments, and 28,942,098 shares of Issuer Class A common stock (Class A Common Stock). Pursuant to the terms of the Purchase Agreement, limited liability companies managed by the Reporting Person received 6,381,734 shares of Class A Common Stock in the Acquisition.
Key Figures
Cash consideration for Kashiv acquisition: $375,000,000
Stock consideration for Kashiv acquisition: 28,942,098 shares
Shares received by LLCs managed by reporting person: 6,381,734 shares
+3 more
6 metrics
Cash consideration for Kashiv acquisition
$375,000,000
Aggregate cash consideration to acquire 100% of Kashiv BioSciences, LLC membership interests
Stock consideration for Kashiv acquisition
28,942,098 shares
Total Class A common stock issued as part of Kashiv BioSciences, LLC acquisition
Shares received by LLCs managed by reporting person
6,381,734 shares
Class A common stock issued to limited liability companies managed by Chirag K. Patel
Direct holdings after transaction
1,393,470 shares
Class A common stock directly held by Chirag K. Patel following reported transactions
Indirect holdings by family trusts
21,269,420 shares
Class A common stock held indirectly by family trusts associated with the reporting person
Indirect holdings by LLCs from acquisition entry
6,381,734 shares
Total Class A shares indirectly held "By Limited Liability Companies" after the acquisition-related award
Key Terms
Membership Interest Purchase Agreement, aggregate consideration, purchase price adjustments, Family Trusts, +1 more
5 terms
Membership Interest Purchase Agreement regulatory
"pursuant to a Membership Interest Purchase Agreement, dated as of April 21, 2026"
A membership interest purchase agreement is a contract used when someone buys an ownership stake in a limited liability company (LLC). It spells out what is being sold, the price, any promises about the business’s condition, and who takes responsibility for debts or legal issues—like a receipt and rulebook for the sale. Investors care because it transfers control, affects future cash flow and liabilities, and can change the value and tax treatment of their investment.
aggregate consideration financial
"for an aggregate consideration of $375,000,000 in cash, subject to certain"
purchase price adjustments financial
"$375,000,000 in cash, subject to certain purchase price adjustments, and 28,942,098"
Purchase price adjustments are changes made to the agreed sale price of a company after closing to reflect actual financial facts—like cash on hand, debts, or inventory—found when final accounts are prepared. Think of it as the final bill after a home inspection: the buyer and seller settle differences so the price matches reality. For investors, these adjustments affect the true cost, future earnings and cash flow from a deal, and therefore the value of the investment.
Family Trusts financial
"total shares following transaction 21,269,420.0000, nature_of_ownership By Family Trusts"
Class A common stock financial
"28,942,098 shares of Issuer Class A common stock (Class A Common Stock)"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Amneal (AMRX) report for Chirag K. Patel?
Amneal reported that Chirag K. Patel, President & Co-CEO, indirectly acquired 6,381,734 shares of Class A common stock on August 10, 2026 via limited liability companies he manages, in connection with Amneal’s acquisition of Kashiv BioSciences, LLC.
What was the total consideration Amneal (AMRX) paid for Kashiv BioSciences, LLC?
A subsidiary of Amneal paid $375,000,000 in cash, subject to purchase price adjustments, plus 28,942,098 shares of Class A common stock as aggregate consideration to acquire 100% of Kashiv BioSciences, LLC’s membership interests.
AI-generated analysis. How Rhea-AI works. Not financial advice.
